IDEAYA Biosciences (IDYA)
Market Price (7/18/2026): $36.01 | Market Cap: $3.2 BilSector: Health Care | Industry: Biotechnology
IDEAYA Biosciences (IDYA)
Market Price (7/18/2026): $36.01Market Cap: $3.2 BilSector: Health CareIndustry: Biotechnology
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -20% Strong revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is 3118% Low stock price volatilityVol 12M is 49% Megatrend and thematic driversMegatrends include Precision Medicine, and Aging Population & Chronic Disease. Themes include Targeted Therapies, Oncology Treatments, Show more. | Weak multi-year price returns2Y Excs Rtn is -43%, 3Y Excs Rtn is -7.6% Meaningful short interestShort Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 12% | Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -183 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -81% Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 22% Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -38%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -39% Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -8.6% Key risksIDYA key risks include [1] the uncertain clinical and regulatory success of its precision oncology pipeline and [2] its ongoing unprofitability and need for future funding. |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -20% |
| Strong revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is 3118% |
| Low stock price volatilityVol 12M is 49% |
| Megatrend and thematic driversMegatrends include Precision Medicine, and Aging Population & Chronic Disease. Themes include Targeted Therapies, Oncology Treatments, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -43%, 3Y Excs Rtn is -7.6% |
| Meaningful short interestShort Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 12% |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -183 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -81% |
| Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 22% |
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -38%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -39% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -8.6% |
| Key risksIDYA key risks include [1] the uncertain clinical and regulatory success of its precision oncology pipeline and [2] its ongoing unprofitability and need for future funding. |
Qualitative Assessment
AI Analysis | Feedback
IDEAYA Biosciences (IDYA) stock has gained about 10% since 3/31/2026 because of the following key factors:
1. Positive Clinical Trial Results and Accelerated Regulatory Pathway for Darovasertib.
IDEAYA Biosciences announced positive topline results in fiscal Q2 2026 from the registrational Phase 2/3 OptimUM-02 trial of darovasertib in combination with crizotinib for first-line HLA*A2-negative metastatic uveal melanoma. The trial met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in median progression-free survival (PFS) of 6.9 months compared to 3.1 months for investigator's choice of therapy. This positive outcome led to the initiation of the U.S. Food and Drug Administration's (FDA) Real-Time Oncology Review (RTOR) submission process in May 2026, targeting a New Drug Application (NDA) filing in the second half of 2026 for potential accelerated approval.
2. Expansion and Validation of Pipeline through Strategic Collaborations.
In fiscal Q2 2026, IDEAYA advanced its pipeline with the initiation of a Phase 1/2 clinical combination study for IDE892, a potential best-in-class MTA-Cooperative PRMT5 inhibitor, in MTAP-deleted pancreatic and lung cancers on June 15, 2026. Furthermore, the company established a clinical collaboration with Roche on June 3, 2026, to evaluate IDE892 in combination with Roche's RG6505 in MTAP-deleted RAS-mutant pancreatic cancer, highlighting its robust pipeline and strategic partnerships.
Show more
IDEAYA Biosciences (IDYA) stock has gained about 10% since 3/31/2026 because of the following key factors:
1. Positive Clinical Trial Results and Accelerated Regulatory Pathway for Darovasertib.
IDEAYA Biosciences announced positive topline results in fiscal Q2 2026 from the registrational Phase 2/3 OptimUM-02 trial of darovasertib in combination with crizotinib for first-line HLA*A2-negative metastatic uveal melanoma. The trial met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in median progression-free survival (PFS) of 6.9 months compared to 3.1 months for investigator's choice of therapy. This positive outcome led to the initiation of the U.S. Food and Drug Administration's (FDA) Real-Time Oncology Review (RTOR) submission process in May 2026, targeting a New Drug Application (NDA) filing in the second half of 2026 for potential accelerated approval.
2. Expansion and Validation of Pipeline through Strategic Collaborations.
In fiscal Q2 2026, IDEAYA advanced its pipeline with the initiation of a Phase 1/2 clinical combination study for IDE892, a potential best-in-class MTA-Cooperative PRMT5 inhibitor, in MTAP-deleted pancreatic and lung cancers on June 15, 2026. Furthermore, the company established a clinical collaboration with Roche on June 3, 2026, to evaluate IDE892 in combination with Roche's RG6505 in MTAP-deleted RAS-mutant pancreatic cancer, highlighting its robust pipeline and strategic partnerships.
3. Strengthened Financial Position through Successful Public Offering.
IDEAYA Biosciences successfully completed a public offering in June 2026, raising approximately $300 million through the sale of common stock and pre-funded warrants. This significant capital raise bolstered the company's cash, cash equivalents, and marketable securities to approximately $973 million as of March 31, 2026, extending its cash runway guidance into 2030 and providing financial stability for ongoing research and development activities.
4. Strong Analyst Sentiment and Favorable Price Targets.
Throughout the period, Wall Street analysts maintained a highly positive outlook on IDEAYA Biosciences, with a consensus "Buy" or "Strong Buy" rating. Analysts issued average 12-month price targets ranging from $50.25 to $54.00, representing an upside potential of 32.16% to 43.43% from its then-current trading levels, which likely contributed to increased investor confidence and stock appreciation.
Show less
Stock Movement Drivers
Fundamental Drivers
The 8.1% change in IDYA stock from 3/31/2026 to 7/17/2026 was primarily driven by a 5.1% change in the company's P/S Multiple.| (LTM values as of) | 3312026 | 7172026 | Change |
|---|---|---|---|
| Stock Price ($) | 33.32 | 36.01 | 8.1% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 219 | 225 | 3.0% |
| P/S Multiple | 13.5 | 14.2 | 5.1% |
| Shares Outstanding (Mil) | 89 | 89 | -0.1% |
| Cumulative Contribution | 8.1% |
Market Drivers
3/31/2026 to 7/17/2026| Return | Correlation | |
|---|---|---|
| IDYA | 8.1% | |
| Market (SPY) | 14.3% | 24.1% |
| Sector (XLV) | 9.9% | 16.5% |
Fundamental Drivers
The 4.2% change in IDYA stock from 12/31/2025 to 7/17/2026 was primarily driven by a 4.9% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 12312025 | 7172026 | Change |
|---|---|---|---|
| Stock Price ($) | 34.57 | 36.01 | 4.2% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 215 | 225 | 4.9% |
| P/S Multiple | 14.2 | 14.2 | -0.5% |
| Shares Outstanding (Mil) | 89 | 89 | -0.2% |
| Cumulative Contribution | 4.2% |
Market Drivers
12/31/2025 to 7/17/2026| Return | Correlation | |
|---|---|---|
| IDYA | 4.2% | |
| Market (SPY) | 9.3% | 26.8% |
| Sector (XLV) | 4.5% | 25.7% |
Fundamental Drivers
The 71.3% change in IDYA stock from 6/30/2025 to 7/17/2026 was primarily driven by a 3118.1% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 6302025 | 7172026 | Change |
|---|---|---|---|
| Stock Price ($) | 21.02 | 36.01 | 71.3% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 7 | 225 | 3118.1% |
| P/S Multiple | 265.3 | 14.2 | -94.7% |
| Shares Outstanding (Mil) | 88 | 89 | -0.4% |
| Cumulative Contribution | 71.3% |
Market Drivers
6/30/2025 to 7/17/2026| Return | Correlation | |
|---|---|---|
| IDYA | 71.3% | |
| Market (SPY) | 21.3% | 29.8% |
| Sector (XLV) | 21.1% | 29.7% |
Fundamental Drivers
The 53.2% change in IDYA stock from 6/30/2023 to 7/17/2026 was primarily driven by a 374.7% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 6302023 | 7172026 | Change |
|---|---|---|---|
| Stock Price ($) | 23.50 | 36.01 | 53.2% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 47 | 225 | 374.7% |
| P/S Multiple | 24.0 | 14.2 | -40.8% |
| Shares Outstanding (Mil) | 48 | 89 | -45.5% |
| Cumulative Contribution | 53.2% |
Market Drivers
6/30/2023 to 7/17/2026| Return | Correlation | |
|---|---|---|
| IDYA | 53.2% | |
| Market (SPY) | 73.6% | 35.0% |
| Sector (XLV) | 27.1% | 34.5% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| IDYA Return | 69% | -23% | 96% | -28% | 35% | 4% | 157% |
| Peers Return | -22% | -48% | 11% | -55% | 54% | 112% | -33% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 10% | 101% |
Monthly Win Rates [3] | |||||||
| IDYA Win Rate | 67% | 58% | 67% | 25% | 58% | 57% | |
| Peers Win Rate | 42% | 33% | 45% | 40% | 55% | 54% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 57% | |
Max Drawdowns [4] | |||||||
| IDYA Max Drawdown | -30% | -66% | -29% | -47% | -44% | -27% | |
| Peers Max Drawdown | -58% | -66% | -65% | -73% | -58% | -38% | |
| S&P 500 Max Drawdown | -5% | -25% | -10% | -8% | -19% | -9% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: ZNTL, TNGX, KURA, RLAY, BDTX.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 7/17/2026 (YTD)
How Low Can It Go
| Event | IDYA | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -29.8% | -18.8% |
| % Gain to Breakeven | 42.5% | 23.1% |
| Time to Breakeven | 24 days | 79 days |
| 2023 SVB Regional Banking Crisis | ||
| % Loss | -25.3% | -6.7% |
| % Gain to Breakeven | 33.9% | 7.1% |
| Time to Breakeven | 12 days | 31 days |
| 2022 Inflation Shock & Fed Tightening | ||
| % Loss | -65.5% | -24.5% |
| % Gain to Breakeven | 190.1% | 32.4% |
| Time to Breakeven | 389 days | 427 days |
| 2020 COVID-19 Crash | ||
| % Loss | -55.6% | -33.7% |
| % Gain to Breakeven | 125.1% | 50.9% |
| Time to Breakeven | 52 days | 140 days |
In The Past
IDEAYA Biosciences's stock fell -29.8% during the 2025 US Tariff Shock. Such a loss loss requires a 42.5% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
| Event | IDYA | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -29.8% | -18.8% |
| % Gain to Breakeven | 42.5% | 23.1% |
| Time to Breakeven | 24 days | 79 days |
| 2023 SVB Regional Banking Crisis | ||
| % Loss | -25.3% | -6.7% |
| % Gain to Breakeven | 33.9% | 7.1% |
| Time to Breakeven | 12 days | 31 days |
| 2022 Inflation Shock & Fed Tightening | ||
| % Loss | -65.5% | -24.5% |
| % Gain to Breakeven | 190.1% | 32.4% |
| Time to Breakeven | 389 days | 427 days |
| 2020 COVID-19 Crash | ||
| % Loss | -55.6% | -33.7% |
| % Gain to Breakeven | 125.1% | 50.9% |
| Time to Breakeven | 52 days | 140 days |
In The Past
IDEAYA Biosciences's stock fell -29.8% during the 2025 US Tariff Shock. Such a loss loss requires a 42.5% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About IDEAYA Biosciences (IDYA)
IDEAYA Biosciences, Inc. (IDYA) is a precision medicine oncology company dedicated to discovering and developing targeted therapeutics for cancer. The company’s core focus is on "synthetic lethality," an approach that aims to selectively kill cancer cells by exploiting specific genetic vulnerabilities while sparing healthy tissue. IDEAYA identifies patient populations using molecular diagnostics, ensuring that their investigational treatments are directed towards those most likely to benefit from a specific therapeutic strategy.
The company's pipeline features lead product candidates in clinical development. IDE397, a methionine adenosyltransferase 2a (MAT2A) inhibitor, is currently in Phase I trials for patients with solid tumors characterized by methylthioadenosine phosphorylase (MTAP) deletions. Another key asset, IDE196, a protein kinase C (PKC) inhibitor, is undergoing Phase I/II clinical trials for genetically defined cancers that have GNAQ or GNA11 gene mutations, which are notably found in uveal melanoma. Beyond these clinical programs, IDEAYA is also advancing a preclinical pipeline targeting other synthetic lethality pathways, including PARG inhibitors, Pol Theta inhibitors, and WRN inhibitors, each designed for tumors with specific biomarkers such as BRCA mutations or high microsatellite instability.
IDEAYA primarily serves patients suffering from various cancers who possess specific genetic mutations or molecular signatures, allowing for a highly tailored treatment approach. To accelerate its research and development, IDEAYA has established strategic collaborations, including a research agreement with Cancer Research UK and the University of Manchester. Furthermore, the company has forged significant partnerships with pharmaceutical giants like Pfizer Inc. for clinical trials and GlaxoSmithKline plc, underscoring the potential and scientific validation of its innovative cancer therapies.
AI Analysis | Feedback
Here are 1-2 brief analogies for IDEAYA Biosciences (IDYA):
- Like Moderna or BioNTech, but focused on developing highly targeted cancer therapies instead of vaccines.
- A smaller, early-stage Amgen or Gilead Sciences, singularly dedicated to discovering groundbreaking precision oncology drugs.
AI Analysis | Feedback
- IDE397: A methionine adenosyltransferase 2a inhibitor currently in Phase I clinical trial for solid tumors with MTAP deletions.
- IDE196: A protein kinase C inhibitor in Phase I/II clinical trial for genetically defined cancers having GNAQ or GNA11 gene mutations.
- PARG inhibitor program: A preclinical program developing small molecule inhibitors for tumors with a defined biomarker based on genetic mutations and/or molecular signatures.
- Pol Theta inhibitor program: A preclinical program developing inhibitors for tumors with BRCA or other homologous recombination deficiency mutations.
- WRN inhibitor program: A preclinical program developing inhibitors for tumors with high microsatellite instability.
AI Analysis | Feedback
- Pfizer Inc. (NYSE: PFE)
- GlaxoSmithKline plc (NYSE: GSK)
AI Analysis | Feedback
AI Analysis | Feedback
Yujiro S. Hata, President, Chief Executive Officer, Founder, and Director
Mr. Hata founded IDEAYA Biosciences in June 2015 as its first employee, CEO, and Director, and led the company's IPO on NASDAQ in May 2019. From 2015 to 2018, he served as an Executive-in-Residence at 5AM Ventures. Prior to IDEAYA, he was Chief Operating Officer at Flexus Biosciences from 2014 to August 2015, guiding it through its acquisition by Bristol-Myers Squibb in April 2015. He also served as Chief Operating Officer at FLX Bio (later RAPT Therapeutics), a spinout of Flexus Biosciences. From 2010 to 2014, he was Vice President, Corporate Development and Strategy at Onyx Pharmaceuticals, including through its acquisition by Amgen. From 2002 to 2010, Mr. Hata held roles including Chief Business Officer at Enanta Pharmaceuticals, where he established a partnership with Abbott Labs that led to the discovery of protease inhibitors in HCV therapies. His background includes earlier roles at McKinsey, ImClone, and Columbia Medical School. His association with 5AM Ventures and leading Flexus Biosciences through an acquisition indicates a pattern of involvement with and successful exits from privately backed and startup companies.
Joshua Bleharski, Ph.D., Chief Financial Officer
Dr. Bleharski was appointed Chief Financial Officer in February 2025. He joined IDEAYA from J.P. Morgan, where he spent nearly 17 years as Managing Director and Global Co-Head of Biopharma in the Healthcare Investment Banking group. In this role, he advised biotechnology companies on financing and strategic transactions valued at over $65 billion. His prior experience includes serving as a Senior Staff Scientist at a private biotechnology company and completing post-doctoral fellowships at LIAI and UCLA School of Medicine. He holds a Ph.D. in Immunology from UCLA and an MBA from UC Berkeley's Haas School of Business.
Michael White, Ph.D., Senior Vice President, Chief Scientific Officer, Head of Research
Dr. White serves as the Chief Scientific Officer and Head of Research for IDEAYA Biosciences.
Darrin M. Beaupre, M.D., Ph.D., Chief Medical Officer
Dr. Beaupre is the Chief Medical Officer at IDEAYA Biosciences. He previously served as an Assistant Professor in the Department of Interdisciplinary Oncology at the Moffit Cancer Center. His distinctions include receiving a Clinical Scholars in Oncology Award from the National Cancer Institute. Dr. Beaupre completed his Medical Oncology and Hematology Fellowship and post-doctoral research training at the University of Miami Sylvester Cancer Center.
Theodora (Theo) Ross, M.D., Ph.D., Chief Development Officer
Dr. Ross was appointed Chief Development Officer in February 2026. In this role, she is responsible for leading early clinical development for IDEAYA's oncology pipeline and guiding the company's long-term R&D strategy. Prior to joining IDEAYA, Dr. Ross was Vice President, Head of Early Oncology R&D and Site Head for the Bay Area at AbbVie.
AI Analysis | Feedback
Key Risks to IDEAYA Biosciences (IDYA)
- Clinical Trial Failure and Regulatory Approval Risk: IDEAYA Biosciences' primary assets are currently in early-stage clinical trials (Phase I and Phase I/II) or preclinical development. The success of these candidates, such as IDE397 and IDE196, is uncertain. Many drug candidates fail during clinical development due to lack of efficacy, unacceptable safety profiles, or other issues. Even if trials are successful, there is no guarantee that regulatory bodies (like the FDA) will approve the drugs for commercialization. Failure at any stage of development or inability to secure regulatory approval would severely impact the company's prospects and valuation.
- Intellectual Property Protection Risk: As a precision medicine oncology company, IDEAYA Biosciences relies heavily on its ability to discover, develop, and protect proprietary compounds and technologies. The company's competitive advantage and future revenue potential depend on obtaining and maintaining patent protection for its product candidates and related intellectual property. If the company is unable to secure strong patent protection, or if its patents are challenged, invalidated, or circumvented by competitors, it could significantly diminish the value of its pipeline and expose it to competition.
- Intense Competition in the Oncology Market: The field of oncology drug development is highly competitive, with numerous large pharmaceutical companies and biotechnology firms developing similar or alternative therapies. IDEAYA's product candidates, if approved, would compete with existing treatments and new therapies that are continually being developed by others. The ability to successfully commercialize its products will depend on their efficacy, safety, market acceptance, and competitive pricing, all within a rapidly evolving and competitive landscape.
AI Analysis | Feedback
AI Analysis | Feedback
IDEAYA Biosciences (NASDAQ: IDYA) focuses on precision medicine oncology. The addressable markets for its main product candidates are as follows:
- IDE397 (Methionine Adenosyltransferase 2a Inhibitor): This product targets solid tumors with methylthioadenosine phosphorylase (MTAP) deletions. MTAP deletion is found in approximately 15% of solid tumors globally. The global solid tumor market is projected to reach USD 283.8 billion by 2029. Therefore, the estimated global addressable market for IDE397 is approximately USD 42.6 billion. Additionally, the annual incidence of MTAP-deletion solid tumors across priority types such as non-small cell lung cancer, bladder, gastric, and esophageal cancers is estimated to be greater than 50,000 patients in the U.S., EU5 (Germany, France, Italy, Spain, and the UK), and Japan.
- IDE196 (Protein Kinase C Inhibitor): This product is in development for genetically defined cancers having GNAQ or GNA11 gene mutations, primarily metastatic uveal melanoma. GNAQ and GNA11 gene mutations are present in approximately 80% to 90% of uveal melanoma cases. The global uveal melanoma treatment market was valued at USD 1.2 billion in 2024 and is projected to reach USD 2.5 billion by 2035. This market size is global.
AI Analysis | Feedback
IDEAYA Biosciences (NASDAQ: IDYA) is a precision medicine oncology company with a pipeline focused on synthetic lethality. While analysts have recently adjusted down revenue estimates for 2026, forecasts for 2027 and 2028 indicate a potential increase, driven by the advancement and eventual commercialization of its therapeutic candidates and milestone achievements from strategic collaborations.
Here are 3-5 expected drivers of future revenue growth for IDEAYA Biosciences over the next 2-3 years:
- Commercialization of Darovasertib (IDE196) for Uveal Melanoma: Darovasertib, a protein kinase C inhibitor, is IDEAYA's lead product candidate, currently in Phase 2/3 registrational trials for metastatic uveal melanoma (mUM). Topline results for the OptimUM-02 trial, evaluating darovasertib in combination with crizotinib, are anticipated by approximately the last week of March 2026. Furthermore, darovasertib is expected to be in three randomized Phase 3 registrational trials for uveal melanoma (metastatic, neoadjuvant, and adjuvant settings) by the first half of 2026. The company has also received U.S. FDA Breakthrough Therapy Designation for darovasertib in neoadjuvant uveal melanoma. IDEAYA has partnered with Servier for exclusive rights to darovasertib outside the United States, a collaboration that includes an upfront payment, potential milestone payments of up to $320 million, and double-digit royalties on ex-U.S. net sales, while IDEAYA retains all U.S. commercial rights. Commercial readiness activities are ongoing in anticipation of these critical trial results and potential market entry.
- Achievement of Development and Commercial Milestone Payments from Strategic Collaborations: IDEAYA has established partnerships with major pharmaceutical companies, which serve as a significant source of current and future revenue through milestone payments. Notable collaborations include the agreement with Servier for darovasertib (outside U.S. rights), and GlaxoSmithKline (GSK) for the Werner Helicase inhibitor program and the Pol Theta program. For the Werner Helicase inhibitor, IDEAYA is eligible for up to $465 million in development and regulatory milestones, $475 million in commercial milestones, and 50% of U.S. net profits, along with tiered royalties on global non-U.S. net sales. A $7 million milestone was earned from GSK upon IND clearance of IDE275 (Werner Helicase) in October 2024. The Pol Theta Helicase program also has a potential $10 million milestone payment from GSK upon Phase 2 expansion. Additional collaborations, such as with Gilead for the IDE397 combination and Biocytogen for the B7H3/PTK7 Topo-Payload BsADC program, offer further potential milestone payments as these programs advance through development.
- Advancement and Potential Market Entry of IDE849 (DLL3 TOP1 ADC): IDEAYA is progressing IDE849, a DLL3 TOP1 ADC, with the initiation of a monotherapy registrational study in the second line/refractory setting of small cell lung cancer (SCLC) and/or neuroendocrine carcinomas (NEC) targeted by the end of 2026. Preliminary clinical data updates from the IDEAYA-sponsored global Phase 1 trial of IDE849 are also expected by the end of 2026. The successful progression and potential commercialization of IDE849 represent another distinct avenue for product-based revenue growth within the next 2-3 years.
- Progression of Other Clinical and Preclinical Synthetic Lethality Pipeline Programs: Beyond darovasertib and IDE849, IDEAYA has a robust pipeline of synthetic lethality programs that are expected to contribute to future revenue growth through continued milestone payments and eventual product launches. These include IDE397 (MAT2A inhibitor), which has ongoing Phase 1/2 combination trials with updated data expected in 2026; PARG inhibitors (IDE161); Pol Theta inhibitors (IDE705/GSK101); and Werner Helicase inhibitors (IDE275/GSK959). The company is also targeting new IND filings for IDE892 (PRMT5), IDE034 (B7H3/PTK7 ADC), and IDE574 (KAT6/7) in 2025/2026, indicating a continuous stream of potential future therapeutic candidates.
AI Analysis | Feedback
Share Issuance
- IDEAYA Biosciences granted non-qualified stock options to purchase an aggregate of 346,200 shares to three newly hired employees on February 26, 2026, with an exercise price of $31.90.
- On January 29, 2026, the company granted non-qualified stock options to purchase an aggregate of 44,200 shares to a newly hired employee, with an exercise price of $32.99.
Inbound Investments
- IDEAYA Biosciences reported approximately $1.1 billion in cash, cash equivalents, and marketable securities as of September 30, 2025, which is projected to fund operations into 2030.
- The company received a $210.0 million upfront payment from Servier in 2025 related to an exclusive license agreement for darovasertib.
- IDEAYA has strategic partnerships, including one with GlaxoSmithKline (GSK) that could yield up to approximately $3 billion in aggregate cash milestones across its MAT2A, Pol Theta, and Werner Helicase programs.
Capital Expenditures
- Capital expenditures for IDEAYA Biosciences were $2.64 million in 2021, $3.44 million in 2022, and $2.37 million in 2023.
- In 2024, capital expenditures were $3.86 million, and in 2025, they were $2.37 million.
Latest Trefis Analyses
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 15.38 |
| Mkt Cap | 2.1 |
| Rev LTM | 34 |
| Op Inc LTM | -164 |
| FCF LTM | -107 |
| FCF 3Y Avg | -148 |
| CFO LTM | -106 |
| CFO 3Y Avg | -147 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 22.2% |
| Rev Chg 3Y Avg | 944.8% |
| Rev Chg Q | -80.5% |
| QoQ Delta Rev Chg LTM | -8.6% |
| Op Inc Chg LTM | 20.5% |
| Op Inc Chg 3Y Avg | -16.6% |
| Op Mgn LTM | -324.9% |
| Op Mgn 3Y Avg | -2,085.3% |
| QoQ Delta Op Mgn LTM | -18.2% |
| CFO/Rev LTM | -178.6% |
| CFO/Rev 3Y Avg | -1,552.5% |
| FCF/Rev LTM | -184.0% |
| FCF/Rev 3Y Avg | -1,579.0% |
Price Behavior
| Market Price | $36.01 | |
| Market Cap ($ Bil) | 3.2 | |
| First Trading Date | 05/23/2019 | |
| Distance from 52W High | -11.1% | |
| 50 Days | 200 Days | |
| DMA Price | $31.70 | $32.23 |
| DMA Trend | up | up |
| Distance from DMA | 13.6% | 11.7% |
| 3M | 1YR | |
| Volatility | 53.7% | 49.1% |
| Downside Capture | 100.78 | 108.48 |
| Upside Capture | 107.20 | 143.85 |
| Correlation (SPY) | 27.2% | 29.0% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 0.90 | 0.77 | 1.07 | 0.97 | 1.16 | 1.13 |
| Up Beta | 0.97 | 1.49 | 1.74 | 1.76 | 1.78 | 1.08 |
| Down Beta | 1.57 | 1.07 | 0.41 | 0.22 | 0.15 | 0.82 |
| Up Capture | 233% | 133% | 94% | 92% | 197% | 220% |
| Bmk +ve Days | 11 | 24 | 40 | 67 | 140 | 429 |
| Stock +ve Days | 14 | 22 | 31 | 62 | 128 | 381 |
| Down Capture | -57% | -32% | 88% | 97% | 109% | 107% |
| Bmk -ve Days | 10 | 17 | 23 | 58 | 112 | 321 |
| Stock -ve Days | 7 | 18 | 31 | 62 | 122 | 365 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with IDYA | |
|---|---|---|---|---|
| IDYA | 62.9% | 49.0% | 1.15 | - |
| Sector ETF (XLV) | 21.6% | 15.8% | 1.05 | 28.8% |
| Equity (SPY) | 20.2% | 12.6% | 1.18 | 28.7% |
| Gold (GLD) | 19.6% | 28.0% | 0.63 | 9.5% |
| Commodities (DBC) | 30.0% | 19.0% | 1.25 | -10.5% |
| Real Estate (VNQ) | 15.7% | 14.0% | 0.81 | 12.8% |
| Bitcoin (BTCUSD) | -46.4% | 42.8% | -1.33 | 21.3% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with IDYA | |
|---|---|---|---|---|
| IDYA | 16.2% | 58.7% | 0.49 | - |
| Sector ETF (XLV) | 6.2% | 15.0% | 0.23 | 28.7% |
| Equity (SPY) | 12.8% | 17.1% | 0.57 | 31.2% |
| Gold (GLD) | 16.9% | 18.4% | 0.74 | 4.3% |
| Commodities (DBC) | 8.7% | 19.5% | 0.34 | 1.7% |
| Real Estate (VNQ) | 2.9% | 18.9% | 0.05 | 24.4% |
| Bitcoin (BTCUSD) | 13.6% | 53.5% | 0.44 | 17.2% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with IDYA | |
|---|---|---|---|---|
| IDYA | 12.8% | 73.8% | 0.55 | - |
| Sector ETF (XLV) | 10.1% | 16.6% | 0.49 | 25.3% |
| Equity (SPY) | 15.3% | 17.9% | 0.73 | 26.6% |
| Gold (GLD) | 11.0% | 16.1% | 0.55 | 5.9% |
| Commodities (DBC) | 7.0% | 17.9% | 0.31 | 6.9% |
| Real Estate (VNQ) | 5.3% | 20.7% | 0.22 | 22.4% |
| Bitcoin (BTCUSD) | 58.5% | 66.2% | 0.99 | 12.8% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Updated 6/8/2026| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 5/5/2026 | -0.3% | -2.7% | -1.7% |
| 2/17/2026 | 1.6% | 6.1% | 13.2% |
| 11/4/2025 | -2.8% | -1.5% | 14.8% |
| 8/5/2025 | -3.5% | -8.6% | 3.0% |
| 5/6/2025 | -13.3% | -10.4% | 3.1% |
| 2/13/2025 | -5.4% | -1.0% | -15.4% |
| 11/4/2024 | 4.9% | 9.4% | -6.8% |
| 8/6/2024 | -2.7% | 1.6% | 4.1% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 10 | 10 | 14 |
| # Negative | 14 | 14 | 10 |
| Median Positive | 2.7% | 1.8% | 11.1% |
| Median Negative | -2.5% | -3.0% | -10.1% |
| Max Positive | 14.6% | 26.0% | 52.7% |
| Max Negative | -34.8% | -34.8% | -20.0% |
| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 5/5/2026 | -0.3% | -2.7% | -1.7% |
| 2/17/2026 | 1.6% | 6.1% | 13.2% |
| 11/4/2025 | -2.8% | -1.5% | 14.8% |
| 8/5/2025 | -3.5% | -8.6% | 3.0% |
| 5/6/2025 | -13.3% | -10.4% | 3.1% |
| 2/13/2025 | -5.4% | -1.0% | -15.4% |
| 11/4/2024 | 4.9% | 9.4% | -6.8% |
| 8/6/2024 | -2.7% | 1.6% | 4.1% |
| 5/7/2024 | -0.8% | -4.7% | -8.0% |
| 2/20/2024 | -6.6% | -2.0% | -6.0% |
| 11/7/2023 | 1.1% | 0.9% | 5.7% |
| 8/10/2023 | 2.8% | 1.9% | 12.9% |
| 5/9/2023 | 14.6% | 11.5% | 30.8% |
| 3/7/2023 | 6.2% | -5.2% | -16.7% |
| 11/8/2022 | 2.6% | -3.3% | 0.2% |
| 8/15/2022 | -34.8% | -34.8% | -20.0% |
| 5/10/2022 | 12.6% | 26.0% | 52.7% |
| 3/15/2022 | -2.3% | -4.3% | -12.2% |
| 11/15/2021 | 1.5% | 0.8% | -6.4% |
| 8/10/2021 | -1.6% | -0.9% | 16.3% |
| 5/10/2021 | 1.3% | 1.7% | 13.9% |
| 3/23/2021 | -1.6% | -2.6% | -17.2% |
| 11/12/2020 | -1.5% | 1.2% | 9.3% |
| 8/12/2020 | -1.7% | -1.9% | 5.8% |
| SUMMARY STATS | |||
| # Positive | 10 | 10 | 14 |
| # Negative | 14 | 14 | 10 |
| Median Positive | 2.7% | 1.8% | 11.1% |
| Median Negative | -2.5% | -3.0% | -10.1% |
| Max Positive | 14.6% | 26.0% | 52.7% |
| Max Negative | -34.8% | -34.8% | -20.0% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 03/31/2026 | 05/05/2026 | 10-Q |
| 12/31/2025 | 02/17/2026 | 10-K |
| 09/30/2025 | 11/04/2025 | 10-Q |
| 06/30/2025 | 08/05/2025 | 10-Q |
| 03/31/2025 | 05/06/2025 | 10-Q |
| 12/31/2024 | 02/18/2025 | 10-K |
| 09/30/2024 | 11/04/2024 | 10-Q |
| 06/30/2024 | 08/06/2024 | 10-Q |
| 03/31/2024 | 05/07/2024 | 10-Q |
| 12/31/2023 | 02/20/2024 | 10-K |
| 09/30/2023 | 11/07/2023 | 10-Q |
| 06/30/2023 | 08/10/2023 | 10-Q |
| 03/31/2023 | 05/09/2023 | 10-Q |
| 12/31/2022 | 03/07/2023 | 10-K |
| 09/30/2022 | 11/08/2022 | 10-Q |
| 06/30/2022 | 08/15/2022 | 10-Q |
| Report Date | Filing Date | Filing |
|---|---|---|
| 03/31/2026 | 05/05/2026 | 10-Q |
| 12/31/2025 | 02/17/2026 | 10-K |
| 09/30/2025 | 11/04/2025 | 10-Q |
| 06/30/2025 | 08/05/2025 | 10-Q |
| 03/31/2025 | 05/06/2025 | 10-Q |
| 12/31/2024 | 02/18/2025 | 10-K |
| 09/30/2024 | 11/04/2024 | 10-Q |
| 06/30/2024 | 08/06/2024 | 10-Q |
| 03/31/2024 | 05/07/2024 | 10-Q |
| 12/31/2023 | 02/20/2024 | 10-K |
| 09/30/2023 | 11/07/2023 | 10-Q |
| 06/30/2023 | 08/10/2023 | 10-Q |
| 03/31/2023 | 05/09/2023 | 10-Q |
| 12/31/2022 | 03/07/2023 | 10-K |
| 09/30/2022 | 11/08/2022 | 10-Q |
| 06/30/2022 | 08/15/2022 | 10-Q |
| 03/31/2022 | 05/10/2022 | 10-Q |
| 12/31/2021 | 03/18/2022 | 10-K |
| 09/30/2021 | 11/15/2021 | 10-Q |
| 06/30/2021 | 08/10/2021 | 10-Q |
| 03/31/2021 | 05/10/2021 | 10-Q |
| 12/31/2020 | 03/23/2021 | 10-K |
| 09/30/2020 | 11/12/2020 | 10-Q |
| 06/30/2020 | 08/12/2020 | 10-Q |
| 03/31/2020 | 05/12/2020 | 10-Q |
| 12/31/2019 | 03/24/2020 | 10-K |
| 09/30/2019 | 11/13/2019 | 10-Q |
| 06/30/2019 | 08/12/2019 | 10-Q |
Recent Forward Guidance
Updated 7/12/2026Latest: Q1 2026 Earnings Reported 5/5/2026
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2026 NDA filing completion | |||||||
| 2026 Initiation of registrational trial for IDE849 monotherapy | |||||||
| 2026 Phase 1 combination cohort of IDE892 + IDE397 | |||||||
Prior: Q4 2025 Earnings Reported 2/17/2026
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| Q1 2026 Milestone Payment | 5.00 Mil | ||||||
Q3 2025 Earnings Reported 11/4/2025
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2025 OptimUM-10 Target Enrollment | 450 | 12.5% | Raised | Guidance: 400 for 2025 | |||
| 2025 PB Cohort Enrollment | 330 | -17.5% | Lowered | Guidance: 400 for 2025 | |||
Investor Activity (13F)
Updated Jul 18, 2026Active managers (13F portfolio over $250M, at least 3 holdings) with a position over $5M that is either over 10% of their portfolio or held in a concentrated book of 50 or fewer total positions. Index/ETF, sovereign, bank, community-bank and charitable/donor-advised filers are excluded.
Industry Resources
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.